# Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

> **NCT01933802** · PHASE1 · COMPLETED · sponsor: **Tisch Multiple Sclerosis Research Center of New York** · enrollment: 20 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** intrathecal administration of autologous MSC-NP

## Key facts

- **NCT ID:** NCT01933802
- **Lead sponsor:** Tisch Multiple Sclerosis Research Center of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-12
- **Final completion:** 2017-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933802, "Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01933802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*